Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Access Program for Ulefnersen in Children, Adolescents and Adults With FUS-associated Amyotrophic Lateral Sclerosis (FUS-ALS)

NCT07862959 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Development & Commercialization, Inc. as lead sponsor.

NCT NCT07862959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07862959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Access Program for Ulefnersen in Children, Adolescents and Adults With FUS-associated Amyotrophic Lateral Sclerosis (FUS-ALS)
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis